All peptide therapies at Saving Face are prescribed under medical supervision following a full consultation and lab work
Regulation 503A/503B pharmacy compounding under federal law Clinical Trials CJC-1295 reached Phase 2
V., Wu, B., Liu, Y
Moreover, in subjects with diabetes who were at high risk of cardiovascular events, treatment with GLP-1R agonists based on the structure of endogenous GLP-1, namely liraglutide, semaglutide, albiglutide, and dulaglutide, has demonstrated reductions in major adverse cardiovascular events (MACEs) that appear to be unrelated to the glycemic effects of these agents (1316)
An investigation of the antidepressant-like effect of Jiaotaiwan in rats by nontargeted metabolomics based on ultra-high-performance liquid chromatography quadrupole time-of-flight mass spectrometry
One day of intranasal UCT-MSC-EXs therapy began in November 2022, and his second 1-day treatment of intranasal UCT-MSC-EXs began in January 2023